Glaukos Corporation (NYSE: GKOS) is an ophthalmic medical technology company focused on the development and commercialization of breakthrough devices and drugs to transform the treatment of eye diseases. The company pioneered Micro-Invasive Glaucoma Surgery (MIGS) to revolutionize the traditional treatment of glaucoma using a nanotechnology stent, improving the standard of care for this blinding eye disease around the world. Their very strong revenue growth and industry leadership positioned them for a robust NYSE IPO in 2015. In 2019 Glaukos acquired InterWest portfolio company Avedro (NASDAQ: AVDR), maker of the first and only FDA-approved cross-linking technology for progressive keratoconus, enabling entry into the large corneal health market. Through M&A, licensing, and internal R&D, Glaukos continues to build a deep pipeline leveraging its platform technologies to build a comprehensive and proprietary portfolio of surgical and pharmaceutical therapies for glaucoma, corneal health, and retinal diseases, positioning it as one of the leading therapeutic companies in ophthalmology. Gil Kliman led InterWest’s early-stage investments in both Glaukos and Avedro and continues to serve on the Glaukos board.